Blog
RSS FeedPosted by Michael Wonder on 16 Nov 2016
Trump should be good medicine for the pharmaceutical industry. Here’s why
15 November 2016 - The holidays came early for the pharmaceutical industry this year. ...
Posted by Michael Wonder on 15 Nov 2016
Trump just dropped a big hint to the pharmaceutical industry
14 November 2016 - A single sentence in President-elect Donald Trump's health-care platform sends a strong hint to the drug ...
Posted by Michael Wonder on 15 Nov 2016
Pharmaceutical companies' strategies for reaching the poor are maturing but expansion is gradual
14 November 2016 - Pharmaceutical companies are getting more sophisticated in the way they get products to poor people and are ...
Posted by Michael Wonder on 14 Nov 2016
Modelling and simulation in the development of medicines
14 November 2016 - Watch live broadcast of expert discussion at EMA. ...
Posted by Michael Wonder on 14 Nov 2016
How to facilitate development of cancer treatment based on genetically modified T-cells
8 November 2016 - Watch live broadcast of expert discussion at EMA. ...
Posted by Michael Wonder on 13 Nov 2016
How big data can be used for the development and regulation of medicines
8 November 2016 - EMA workshop broadcast live on 14-15 November. ...
Posted by Michael Wonder on 26 Oct 2016
Big pharma is gearing up to defend drug prices
25 October 2016 - The skyrocketing costs of prescription drugs has been noticeably absent from discussion in the presidential debates — ...
Posted by Michael Wonder on 20 Oct 2016
Members unite in response to R&D tax incentive review
20 October 2016 - More than 100 members have attended AusBiotech consultation meetings this week or made submissions, as the ...
Posted by Michael Wonder on 20 Oct 2016
Opening up clinical data on new medicines
20 October 2016 - EMA provides public access to clinical reports. ...
Posted by Michael Wonder on 17 Oct 2016
FDA awards 21 grants to stimulate product development for rare diseases
17 October 2016 - The U.S. FDA today announced that it has awarded 21 new clinical trial research grants totaling ...
Posted by Michael Wonder on 12 Oct 2016
Undermining value-based purchasing — lessons from the pharmaceutical industry
12 October 2016 - In 2015, the U.S. Department of Health and Human Services announced a goal of linking at ...
Posted by Michael Wonder on 12 Oct 2016
What experimental drug? Most companies don’t post compassionate use policies
11 October 2016 - As patients clamour for greater access to experimental medicines, a survey released Tuesday finds that ...
Posted by Michael Wonder on 11 Oct 2016
Biotech sector crafts response to R&D tax incentive review
11 October 2016 - AusBiotech members are invited to gather at briefings in Sydney, Brisbane and Melbourne to contribute to ...
Posted by Michael Wonder on 09 Oct 2016
Teva and Celltrion announce exclusive biosimilar commercial partnership
6 October 2016 - Teva Pharmaceutical Industries Ltd and Celltrion Healthcare have announced that the companies have entered into an exclusive ...
Posted by Michael Wonder on 06 Oct 2016
Why the drug industry and its critics are both wrong about how R&D spending affects pricing
6 October 2016 - The drug industry often claims that high prices are due to its high R&D costs, while ...